<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636632</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-MYC-2020-1104</org_study_id>
    <nct_id>NCT04636632</nct_id>
  </id_info>
  <brief_title>Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma</brief_title>
  <official_title>Weekly Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma: a Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an opene-label, single center, randomized prospective pilot study to compare the&#xD;
      efficacy of weekly versus triweekly fosaprepitant regimens for the prevention of nausea and&#xD;
      emesis during concurrent chemoradiotherapy for nasopharyngeal carcinoma (NPC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scheme:&#xD;
&#xD;
      Eligible fosaprepitant sensitive (complete response [defined as no emesis and no use of&#xD;
      rescue antiemetics] during the overall phase [0 to 120 hours] of all cycles of&#xD;
      cisplatin-based induction chemotherapy) NPC patients will be randomized to 2 arms at 1:1&#xD;
      ratio.&#xD;
&#xD;
        -  Weekly Arm: fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during&#xD;
           concurrent chemoradiotherapy.&#xD;
&#xD;
        -  Triweekly Arm: fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during&#xD;
           concurrent chemoradiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 11, 2020</start_date>
  <completion_date type="Anticipated">April 11, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 11, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of subjects with complete response (CR) overall</measure>
    <time_frame>7 weeks</time_frame>
    <description>defined as no emesis and no use of rescue therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects with complete control (CC) overall</measure>
    <time_frame>7 weeks</time_frame>
    <description>defined as no emesis and no use of rescue therapy and no significant nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects with sustained no emesis overall</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects with no nausea overall</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects with no significant nausea overall</measure>
    <time_frame>7 weeks</time_frame>
    <description>defined as no or mild nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects with CR in the 24 hours following initiation of radiotherapy and concomitant cisplatin</measure>
    <time_frame>24 hours</time_frame>
    <description>defined as no emesis and no use of rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects with CR in the 120 hours following initiation of radiotherapy and concomitant cisplatin</measure>
    <time_frame>120 hours</time_frame>
    <description>defined as no emesis and no use of rescue therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the mean time to first emetic episode</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) overall</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&amp;N35) overall</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Weekly Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fosaprepitant 150mg/m2 weekly in concurrent with radiotherapy during concurrent chemoradiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triweekly Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fosaprepitant 150mg/m2 triweekly in concurrent with chemotherapy during concurrent chemoradiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fosaprepitant</intervention_name>
    <description>fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy</description>
    <arm_group_label>Triweekly Arm</arm_group_label>
    <arm_group_label>Weekly Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with newly histologically confirmed non-keratinizing nasopharyngeal&#xD;
             carcinoma, including WHO II or III&#xD;
&#xD;
          -  Stage II - IVa NPC patients (according to the 8th AJCC edition)&#xD;
&#xD;
          -  Male and no pregnant female&#xD;
&#xD;
          -  Scheduled for cisplatin-based induction chemotherapy and concomitant triweekly&#xD;
             cisplatin (≥ 70 mg/m2)&#xD;
&#xD;
          -  Fosaprepitant sensitive (complete response [defined as no emesis and no use of rescue&#xD;
             antiemetics] during the overall phase [0 to 120 hours] of all cycles of&#xD;
             cisplatin-based induction chemotherapy)&#xD;
&#xD;
          -  Age between 18-70&#xD;
&#xD;
          -  Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count&#xD;
             ≥100000/μL&#xD;
&#xD;
          -  Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase&#xD;
             (AST) &lt;2.0×upper limit of normal (ULN)&#xD;
&#xD;
          -  Adequate renal function: creatinine clearance ≥60 ml/min&#xD;
&#xD;
          -  Satisfactory performance status: Karnofsky scale (KPS) ≥ 70&#xD;
&#xD;
          -  Without radiotherapy or chemotherapy&#xD;
&#xD;
          -  Patients must give signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of relapse or distant metastasis&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  History of prior malignancy or previous treatment for NPC&#xD;
&#xD;
          -  Had other current malignant diagnoses apart from non-melanoma skin cancers&#xD;
&#xD;
          -  Emesis or clinically significant nausea (moderate or severe) in the 24 h before the&#xD;
             first dose of study medication&#xD;
&#xD;
          -  Drugs with antiemetic activity were not allowed for the 24 h before receiving the&#xD;
             first dose of study medication&#xD;
&#xD;
          -  Known history of central nervous system disease (e.g., a seizure disorder or brain&#xD;
             metastases )&#xD;
&#xD;
          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the&#xD;
             compliance of the trial, for example, unstable cardiac disease requiring treatment,&#xD;
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose&#xD;
             &gt;1.5×ULN), and emotional disturbance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Yuan Chen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD,PhD</last_name>
    <phone>86-20-87343361</phone>
    <email>chenmy@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qi Yang, MD,PhD</last_name>
    <phone>86-14749543956</phone>
    <email>yangqi@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <phone>86-20-8734-3361</phone>
      <email>chmingy@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

